This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
NanoViricides, Inc. (OTC BB:
NNVC) (the "Company") announced today that its President, Dr. Anil Diwan, has been invited to present a seminar at the University of California, Los Angeles. This seminar will be hosted by the Center for Biological Physics, jointly with the California NanoSystems Institute. The seminar is scheduled for Friday, 22nd of March.
“I am honored to have this opportunity to discuss our work with eminent biophysicists that are researching the interactions and structural stability of viruses,” said Anil Diwan, PhD, President of the Company, adding, “Biophysics is the key to understanding our approach to develop nanoviricides®, our novel biomimetic agents designed to destroy viruses.”
Dr. Diwan’s talk is entitled "Designing a Nanoviricide ® - Biophysics is the Key".
A "nanoviricide ®", is a biomimetic decoy designed to fool a virus particle into binding to it and thereby capturing the virus particle and rendering it harmless. It is constructed by chemically attaching virus-binding ligands to a polymeric micelle. Biophysics is of prime importance in designing these structures. The biomimetic ligands tend to have poor energies of interaction with the virus particle per ligand, yet a large number of ligands enable a successful interaction with the virus particle. Additionally, the nanoviricide competes with cells for binding to the virus particle, and must provide a substantially more efficient interaction than the cell-virus interaction, in order to achieve a therapeutic effect. The nanoviricide also must be able to exercise its effect in the biological matrix, be it in the bloodstream, plasma, mucosa, or other extracellular spaces. Further, it should have minimal undesirable interaction with the matrix and host cells so that sufficient material is available for clearing out a fulminant viral infection from a patient's body. In addition, the nanoviricide needs to be able to distribute itself within the body, across various barriers, so that it can reach the spaces where the virus particles are present. NanoViricides, Inc. has demonstrated that highly effective antiviral treatments can be created against a large number of viruses, despite these design challenges. The challenges and opportunities for understanding the behavior of virus-nanoviricide interactions, and the results from studies of nanoviricides development against various viruses such as influenza, HIV, Herpesvirus, adenoviruses, Dengue viruses, will be discussed.